TY - JOUR
T1 - CD23+ mantle cell lymphoma
T2 - A clinical pathologic entity associated with superior outcome compared with CD23- disease
AU - Kelemen, Katalin
AU - Peterson, Lo Ann C.
AU - Helenowski, Irene
AU - Goolsby, Charles L.
AU - Jovanovic, Borko
AU - Miyata, Sarah
AU - Aranha, Olivia
AU - Rosen, Steven T.
AU - Winter, Jane N.
AU - Nelson, Beverly P.
AU - Gordon, Leo I.
AU - Evens, Andrew M.
PY - 2008/8
Y1 - 2008/8
N2 - Mantle cell lymphoma (MCL) commonly lacks expression of CD23. However, a significant minority of MCLs express CD23, as assessed by flow cytometric immunophenotyping (FCIP). The aims of our study were to investigate the expression of CD23 by FCIP in patients with MCL and to correlate CD23 expression with pathologic and clinical parameters, including outcome. We studied 53 patients with untreated MCL who had CD23 expression determined by FCIP. At diagnosis, 14 MCLs (26%) were CD23+ at all tissue sites, whereas 33 (62%) were CD23-, and 6 (11%) had discordant CD23 expression among different tissue sites. Patients with CD23- MCL had extranodal disease more commonly compared with patients with CD23+ MCL. Moreover, with 57-month median follow-up, the 4-year event-free and overall survival rates for CD23+ MCL were 45% and 75%, respectively, compared with 19% and 51% for CD23- MCL. In multivariate Cox regression analysis, CD23 status and leukemicphase MCL were the most important factors predicting outcome.
AB - Mantle cell lymphoma (MCL) commonly lacks expression of CD23. However, a significant minority of MCLs express CD23, as assessed by flow cytometric immunophenotyping (FCIP). The aims of our study were to investigate the expression of CD23 by FCIP in patients with MCL and to correlate CD23 expression with pathologic and clinical parameters, including outcome. We studied 53 patients with untreated MCL who had CD23 expression determined by FCIP. At diagnosis, 14 MCLs (26%) were CD23+ at all tissue sites, whereas 33 (62%) were CD23-, and 6 (11%) had discordant CD23 expression among different tissue sites. Patients with CD23- MCL had extranodal disease more commonly compared with patients with CD23+ MCL. Moreover, with 57-month median follow-up, the 4-year event-free and overall survival rates for CD23+ MCL were 45% and 75%, respectively, compared with 19% and 51% for CD23- MCL. In multivariate Cox regression analysis, CD23 status and leukemicphase MCL were the most important factors predicting outcome.
KW - CD23
KW - Disease outcome
KW - Flow cytometric immunophenotyping
KW - Mantle cell lymphoma
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=48649106006&partnerID=8YFLogxK
U2 - 10.1309/R94MAFJY5EA4A8C3
DO - 10.1309/R94MAFJY5EA4A8C3
M3 - Article
C2 - 18628084
AN - SCOPUS:48649106006
SN - 0002-9173
VL - 130
SP - 166
EP - 177
JO - American journal of clinical pathology
JF - American journal of clinical pathology
IS - 2
ER -